Key Points
- Pharvaris CFO David Nassif sold 6,000 shares at an average price of $36.47, generating $218,820. The transaction reduced his holdings by 4.99% to 114,300 shares.
- Pharvaris reported a quarterly loss of $0.81 per share, missing the $0.75 consensus estimate; analysts expect a full-year loss of $3.12 per share.
- Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $59.87 versus the stock’s reported opening price of $33.07.
Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) CFO David Nassif sold 6,000 shares of Pharvaris stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $36.47, for a total value of $218,820.00. Following the completion of the transaction, the chief financial officer owned 114,300 shares of the company's stock, valued at approximately $4,168,521. This trade represents a 4.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.
Pharvaris Stock Performance
NASDAQ:PHVS opened at $33.07 on Thursday. The stock's fifty day moving average is $35.36 and its 200 day moving average is $31.93. Pharvaris N.V. has a fifty-two week low of $20.65 and a fifty-two week high of $43.25. The firm has a market capitalization of $2.16 billion, a PE ratio of -10.84 and a beta of -2.33.
Pharvaris (NASDAQ:PHVS - Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Equities analysts forecast that Pharvaris N.V. will post -3.12 EPS for the current year.
Analysts Set New Price Targets
A number of analysts recently weighed in on PHVS shares. Wells Fargo & Company increased their price objective on shares of Pharvaris from $55.00 to $65.00 and gave the stock an "overweight" rating in a research report on Wednesday, September 9th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $65.00 price target on shares of Pharvaris in a report on Monday, September 14th. HSBC upgraded Pharvaris to an "overweight" rating in a report on Thursday, August 13th. Leerink Partners increased their target price on Pharvaris from $50.00 to $65.00 and gave the stock an "outperform" rating in a research note on Wednesday, September 9th. Finally, Citizens Jmp lifted their target price on Pharvaris from $75.00 to $79.00 and gave the stock a "market outperform" rating in a research report on Wednesday, September 9th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $59.87.
Check Out Our Latest Stock Report on PHVS
Hedge Funds Weigh In On Pharvaris
Institutional investors have recently modified their holdings of the stock. venBio Partners LLC bought a new position in Pharvaris in the second quarter worth approximately $160,569,809. Wellington Management Group LLP lifted its holdings in shares of Pharvaris by 12.9% in the 2nd quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company's stock worth $82,748,000 after buying an additional 274,034 shares during the period. Commodore Capital LP grew its position in shares of Pharvaris by 1.6% during the 1st quarter. Commodore Capital LP now owns 1,918,970 shares of the company's stock worth $54,211,000 after buying an additional 29,525 shares in the last quarter. 5AM Venture Management LLC purchased a new position in shares of Pharvaris during the second quarter valued at $27,581,008. Finally, Seven Fleet Capital Management LP increased its stake in shares of Pharvaris by 144.6% during the second quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company's stock valued at $26,782,000 after buying an additional 457,804 shares during the period.
About Pharvaris
(
Get Free Report)
Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.
Pharvaris' lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
